GSK3B and esophageal squamous cell carcinoma: These GSK3β inhibitors decreased the number of EdU-positive proliferating cells (Fig. 2B, Supplementary Information, Fig. S5A) and increased the incidence of apoptosis in ESCC cells (Fig. 2C).